These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Progressive drug licensing: an opportunity to achieve transparency and accountability? Wright JM CMAJ; 2007 Jun; 176(13):1848-9. PubMed ID: 17576984 [No Abstract] [Full Text] [Related]
5. Responsibility for pharmaceutical company samples. Reti S N Z Med J; 2005 May; 118(1215):U1472. PubMed ID: 15915193 [No Abstract] [Full Text] [Related]
6. An overview of Canadian and U.S. approaches to drug regulation and responses to postmarket adverse drug reactions. Cheung RY; Goodwin SH J Diabetes Sci Technol; 2013 Mar; 7(2):313-20. PubMed ID: 23566987 [TBL] [Abstract][Full Text] [Related]
7. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. Lexchin J CMAJ; 2005 Mar; 172(6):765-7. PubMed ID: 15767610 [No Abstract] [Full Text] [Related]
8. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada. Openshaw MS Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902 [TBL] [Abstract][Full Text] [Related]
9. What's happening with pharmaceuticals? And how will it impact your practice? Williams B Tenn Med; 2005 May; 98(5):213-6. PubMed ID: 15934528 [No Abstract] [Full Text] [Related]
10. [Importing medicines with quality assurance]. Agência Nacional de Vigilância Sanitária - Anvisa Rev Saude Publica; 2004 Apr; 38(2):337-8. PubMed ID: 15122397 [No Abstract] [Full Text] [Related]
12. Response to "The common drug review: a NICE start for Canada?". Lee KM; la Fleur DP Health Policy; 2007 Jan; 80(1):1. PubMed ID: 16597473 [No Abstract] [Full Text] [Related]
13. Health Canada proposes new regulatory regime for drugs. Kondro W CMAJ; 2007 Apr; 176(9):1261-2. PubMed ID: 17452653 [No Abstract] [Full Text] [Related]
14. An underrecognized challenge in evaluating postmarketing drug safety. Roden DM Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350 [No Abstract] [Full Text] [Related]
15. Issues in the approval of, access to, and post-marketing follow-up of new drugs in Canada: a personal viewpoint. Rawson NS Pharmacoepidemiol Drug Saf; 2002 Jun; 11(4):335-40; discussion 341-2. PubMed ID: 12138603 [No Abstract] [Full Text] [Related]
16. Legalization of drugs not the answer. Brock IG; Gurekas V CMAJ; 2000 Oct; 163(8):954-6. PubMed ID: 11068565 [No Abstract] [Full Text] [Related]
17. Postmarketing modifications in the safety labeling of the new antiepileptics. Buck ML; Gurka MJ; Goodkin HP Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758 [No Abstract] [Full Text] [Related]
18. A new era in drug regulation? Dresser R Hastings Cent Rep; 2005; 35(3):10-1. PubMed ID: 16092391 [No Abstract] [Full Text] [Related]
19. [Current status of cosmetic product regulation]. Pochet A Ann Dermatol Venereol; 2007 Mar; 134(3 Pt 2):2S46-54. PubMed ID: 17563715 [No Abstract] [Full Text] [Related]
20. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]